KR102229760B1
|
|
Fraction of Melissa Leaf Extract and Novel Pharmaceutical Composition Comprising the Same
|
KR102121969B1
|
|
Pharmaceutical Composition Comprising Fraction of Melissa Leaf Extract
|
KR20200091925A
|
|
Composition comprising a horse chestnut extract
|
KR20180001047A
|
|
Composition of an extract of horse chestnut
|
KR20090020285A
|
|
A fraction of melissa leaf extract and a composition comprising the same
|
KR20080071017A
|
|
Method for producing extract of horse chestnut leaf
|
KR100645385B1
|
|
Composition for anti-obesity
|
KR20060115526A
|
|
Composition for angiogenesis inhibitor
|
KR100620751B1
|
|
Composition for radiosensitization
|
US2006246157A1
|
|
Composition for the prevention or treatment of diseases associated with angiogenesis
|
KR20040062018A
|
|
Pharmaceutical compositions for angiogenesis inhibition containing phenylthionocarbamate derivatives or its pharmaceutically acceptable salts
|
EP1438059A1
|
|
Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
|
KR20030035912A
|
|
Composition for inhibiting angiogenesis containing an extract of horse chestnut
|
KR20030071993A
|
|
Compositions comprising Nm23 protein for the use of matrix metalloproteinase inhibitor and angiogenesis inhibitor
|
KR20030060384A
|
|
Expression system of human serum albumin-timp-2 fusion protein and recombinant human serum albumin- timp-2 protein
|
EP1349558A1
|
|
Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
|
KR20020046193A
|
|
Composition containing melissa extract for the use of angiogenesis inhibitor
|
KR20030036993A
|
|
Pharmaceutical composition for inhibiting matrix metalloproteinase activity comprising chalcone or its derivatives
|
WO0211745A1
|
|
Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase
|
WO0209741A1
|
|
The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
|